In 2014, Dr. Schinazi working together with the Egyptian government and Gilead Sciences, agreed to provide Egypt with the drug Sofosbuvir (Sovaldi) for about US$1,000, which is only one percent of its market price. Also working with Pharco, an Egyptian Pharmaceutical company Sovaldi is now available for less than US$120 per cure. In Egypt, there is currently a total of around 12 million Egyptians infected with hepatitis C.[1]